Physician profile
Sean Baxter
NPI 1598200438
$708.37
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $456 · 2022: $252.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $344.75 | 2021-2022 | |
| Abbott Laboratories | $77.69 | 2021-2022 | |
| Lilly USA, LLC | $68.00 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $34.81 | 2021-2022 | |
| Glaxosmithkline, LLC. | $29.17 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.17 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $24.18 | 2021 | |
| Merck Sharp & Dohme LLC | $19.43 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.15 | 2021 | |
| Xeris Pharmaceuticals, INC. | $15.57 | 2021 | |
| Dynavax Technologies Corporation | $14.77 | 2021 | |
| Esperion Therapeutics, INC. | $14.50 | 2021 | |
| Hikma Pharmaceuticals USA | $12.09 | 2021 | |
| Eyevance Pharmaceuticals LLC | $12.09 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sean Baxter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.